Physician

Gavin Mark Melmed, MD

According to 2025 Medicare claims, Gavin Melmed, MD (NPI: 1700094497) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Dallas, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1003083445; TIN: 752131429) and primary practice location at 75044-2210.

Melmed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 583 traditional Medicare patients, billed 146,948 HCPCS/CPT codes, and received $2,706,565 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,388 prescription claims across 244 beneficiaries totaling $3,238,339 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 38 claims. Open Payments data shows 105 records totaling $3,151. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,174,731 to $2,706,565. Similarly, Part D prescription costs have moved sharply higher in recent years, from $287,038 to $3,238,339. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,513 to $1,881.